ONCO (Onconetix) Debt-to-Revenue : 6.22 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Onconetix Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Onconetix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $9.97 Mil. Onconetix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.15 Mil. Onconetix's annualized Revenue for the quarter that ended in Sep. 2024 was $1.63 Mil. Onconetix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 6.21.

Onconetix Debt-to-Revenue Historical Data

The historical data trend for Onconetix's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix Debt-to-Revenue Chart

Onconetix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

170.45

Onconetix Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial													N/A	42.61	5.50	5.42	6.22

Competitive Comparison of Onconetix's Debt-to-Revenue

For the Biotechnology subindustry, Onconetix's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onconetix's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Onconetix's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Onconetix Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Onconetix's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(9.693	+	0.193)	/	0.058
	=	170.45

Onconetix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(9.967	+	0.151)	/	1.628
	=	6.21

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Onconetix Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Onconetix's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Onconetix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202

Website

https://www.onconetix.com

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Executives

Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic	director	BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc	10 percent owner	2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc	other: Manager-Cinti Cornerstone Inv.	2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez	10 percent owner, officer: CEO	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson	officer: Chief Business Officer	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield	officer: CFO	11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable	director	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202